Respiratory medicines are complex, potent and high-performance products. Their physicochemical and aerodynamic properties, such as size, morphology, surface energy, inter-particulate forces and surface 3D geometry, are fundamental to their performance as orally inhaled medicines.

Recognising these crucial requirements, Prosonix generates drug particles from fundamental principles that are specifically designed at the particle level to meet the criteria required for orally inhaled respiratory medicines, such as:

• Consistent and predictable particles
• Assured formulation performance (stable, drug-only formulations possible, no need for excipients)
• Facilitates precise, localised drug targeting
• Enables use of simple, cost-effective devices
• Enables development of Multi-component Particles™

The Company achieves this sophisticated level of control over the physicochemical properties of drug particles via an integrated platform of unique and proprietary particle engineering technologies and formulation processes. This platform is based on the use of ultrasound to control the crystallization process (sonocrystallization) of drug particles.

Prosonix believes its approach to designing and developing respiratory medicines from the individual particle up is radical compared to the conventional approach where large particles are crushed into small particles via a process called jet-milling. The Company also believes that its particle engineering approach avoids the formulation, stability, dose variability and delivery issues that result from using jet-milled drug material.

Prosonix technology has broad applicability - independent of product class, indication or device - and is proven at commercial scale and through partnerships with leading pharmaceuticals companies.